Compare PXS & NRXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PXS | NRXS |
|---|---|---|
| Founded | 2015 | 2011 |
| Country | Greece | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 30.8M | 25.8M |
| IPO Year | N/A | 2023 |
| Metric | PXS | NRXS |
|---|---|---|
| Price | $2.98 | $3.22 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | 23.9K | ★ 802.2K |
| Earning Date | 11-20-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $40,491,000.00 | $3,362,320.00 |
| Revenue This Year | N/A | $31.05 |
| Revenue Next Year | $26.08 | $137.61 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 36.89 |
| 52 Week Low | $2.47 | $1.33 |
| 52 Week High | $4.40 | $6.20 |
| Indicator | PXS | NRXS |
|---|---|---|
| Relative Strength Index (RSI) | 56.03 | 69.82 |
| Support Level | $2.94 | $2.63 |
| Resistance Level | $3.01 | $2.78 |
| Average True Range (ATR) | 0.07 | 0.20 |
| MACD | -0.00 | 0.05 |
| Stochastic Oscillator | 57.89 | 60.00 |
Pyxis Tankers Inc is an international maritime transportation company focused on mid-sized eco-vessels for the product tanker and dry-bulk sectors. It owns a fleet that comprises double-hull product tankers employed under a mix of short- and medium-term time charters and spot charters. The fleet owned by the company includes Konkar Ormi, Pyxis Lamda, Konkar Venture, Pyxis Karteria, and others. Each of the vessels in the fleet is capable of transporting refined petroleum products, such as naphtha, gasoline, jet fuel, kerosene, diesel, fuel oil, and other liquid bulk items, such as vegetable oils and organic chemicals. The company operates under two reportable segments, Tanker Vessels, which derive maximum revenue, and Dry-bulk Vessels.
Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).